Biotie Therapies Oyj engages in research, development, and commercialization of pharmaceutical products. It focuses on products for neurodegenerative and psychiatric disorders. The firm targets disorders including Parkinson's diseases dementia, and primary sclerosing cholangitis. The company was founded by Markku Tapani Jalkanen and Sirpa Tuulikki Jalkanen in June 1992 and is headquartered in Turku, Finland.
Company profile
Ticker
BIOZF
Exchange
CEO
Antero Kallio
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
BIOZF stock data
Latest filings (excl ownership)
CT ORDER
Confidential treatment order
11 May 20
CT ORDER
Confidential treatment order
19 Jul 18
15-12B
Securities registration termination
7 Feb 17
S-8 POS
Registration of securities for employees (post-effective amendment)
30 Jan 17
6-K
Current report (foreign)
30 Sep 16
6-K
Current report (foreign)
26 Sep 16
6-K
Current report (foreign)
26 Aug 16
6-K
Current report (foreign)
25 Aug 16
6-K
Biotie Therapies Corp. Applies for Delisting of Its Shares from Nasdaq Helsinki
18 Aug 16
6-K
Current report (foreign)
28 Jul 16
Latest ownership filings
SC 13D/A
Beneficial ownership report (amended)
4 May 16
SC 13D
Beneficial ownership report
25 Apr 16
SC 13G/A
Biotie Therapies Corp.
15 Apr 16
SC 13G/A
Biotie Therapies Corp.
13 Apr 16
SC 13D/A
Biotie Therapies Corp.
13 Apr 16
SC 13G
Biotie Therapies Corp.
16 Feb 16
SC 13G
Biotie Therapies Corp.
12 Feb 16
SC 13D
Biotie Therapies Corp.
20 Jan 16
SC 13G/A
Biotie Therapies Corp.
4 Sep 15
SC 13G
Biotie Therapies Corp.
9 Jul 15
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|